Ultragenyx Pharma (RARE) Reports Q4 Loss of $0.37 on Revenues of $91.54M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
February 11, 2021 4:05 PM EST2020 total revenue of $271.0 million and 2020 Crysvita1 revenue to Ultragenyx of $138.9 million
2021 Crysvita1 revenue in Ultragenyx territories guidance of $180 million to $190 million reaffirmed
Strong Dojolvi launch continues with approximately 130 patients on reimbursed commercial therapy in the United States
Six programs in clinical trials in 2021, including three pivotal stage gene therapy trials
NOVATO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and... More
